EP0853486A4 - Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases - Google Patents

Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases

Info

Publication number
EP0853486A4
EP0853486A4 EP96932773A EP96932773A EP0853486A4 EP 0853486 A4 EP0853486 A4 EP 0853486A4 EP 96932773 A EP96932773 A EP 96932773A EP 96932773 A EP96932773 A EP 96932773A EP 0853486 A4 EP0853486 A4 EP 0853486A4
Authority
EP
European Patent Office
Prior art keywords
viral
aids
cancer
treatment
therapeutic applications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96932773A
Other languages
German (de)
French (fr)
Other versions
EP0853486A2 (en
EP0853486A3 (en
Inventor
Samir Chachoua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0853486A3 publication Critical patent/EP0853486A3/en
Publication of EP0853486A2 publication Critical patent/EP0853486A2/en
Publication of EP0853486A4 publication Critical patent/EP0853486A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
EP96932773A 1995-09-25 1996-09-25 Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases Withdrawn EP0853486A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US428195P 1995-09-25 1995-09-25
US4281P 1995-09-25
PCT/IB1996/001115 WO1997011667A2 (en) 1995-09-25 1996-09-25 Therapeutic applications using horse serum

Publications (3)

Publication Number Publication Date
EP0853486A3 EP0853486A3 (en) 1997-06-12
EP0853486A2 EP0853486A2 (en) 1998-07-22
EP0853486A4 true EP0853486A4 (en) 2001-09-26

Family

ID=21710013

Family Applications (2)

Application Number Title Priority Date Filing Date
EP96932773A Withdrawn EP0853486A4 (en) 1995-09-25 1996-09-25 Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
EP96931214A Withdrawn EP0858327A2 (en) 1995-09-25 1996-09-25 Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP96931214A Withdrawn EP0858327A2 (en) 1995-09-25 1996-09-25 Use of 2-mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(ii)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases

Country Status (5)

Country Link
EP (2) EP0853486A4 (en)
JP (1) JPH11514990A (en)
AU (2) AU6999096A (en)
CA (2) CA2233445A1 (en)
WO (2) WO1997011667A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DK1220678T3 (en) * 1999-10-04 2007-07-09 John Carter Pharmaceutical preparations containing copper, salicylic acid and vitamin C
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
FR2825923B1 (en) * 2001-06-15 2006-04-07 Oreal NO-SYNTHASE INHIBITOR AND USES
KR20030077743A (en) * 2002-03-26 2003-10-04 변현규 The serum of pregancy mare
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
AU2002353346A1 (en) * 2002-09-10 2004-04-30 Samir Chachoua Induced remission therapy
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
CN101138634A (en) 2006-09-07 2008-03-12 于保法 Composition for treating tumour
WO2009070788A1 (en) 2007-11-30 2009-06-04 The Ramaekers Family Trust Compositions and methods for enhancing fertility
US20110311557A1 (en) * 2009-02-11 2011-12-22 Martin Heath Bluth Reciprocal serum/plasma exchange for the treatment of cancer
AU2015353539A1 (en) 2014-11-26 2017-07-13 Baofa Yu Hapten-enhanced chemoimmunotherapy by ultra-minimum incision personalized intratumoral chemoimmunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
DE4236069A1 (en) * 1992-10-26 1994-04-28 Werner Dr Bergmann Homeopathic medicaments for treating HIV infections - prepd. by dilution of infected serum
WO1994028934A1 (en) * 1993-06-07 1994-12-22 Center For Special Immunology Adoptive immune reconstitution treatment for patients with acquired immunodeficiencies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US5310653A (en) * 1989-10-24 1994-05-10 Board Of Regents, The University Of Texas System Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
DE4236069A1 (en) * 1992-10-26 1994-04-28 Werner Dr Bergmann Homeopathic medicaments for treating HIV infections - prepd. by dilution of infected serum
WO1994028934A1 (en) * 1993-06-07 1994-12-22 Center For Special Immunology Adoptive immune reconstitution treatment for patients with acquired immunodeficiencies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198113, Derwent World Patents Index; Class B04, AN 1981-005287, XP002173662 *
LAVERY J P ET AL: "TREATMENT OF CLL AND ARC PATIENTS WITH TRANSFER FACTOR AND ISOLATION AND CHARACTERIZATION OF LOW MOLECULAR WEIGHT IMMUNOMODULATORS FROM TRANSFER FACTOR", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY,MOSBY - YEARLY BOOK, INC,US, vol. 81, no. 1, 1988, pages 215, XP001010534, ISSN: 0091-6749 *
See also references of WO9711667A3 *
SIMONE DE C ET AL: "CLINICAL AND IMMUNOLOGIC EFFECTS OF COMBINATION THERAPY WITH INTRAVENOUS IMMUNOGLOBULINS AND AZT IN HIV-INFECTED PATIENTS", IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY,MARCEL DEKKER, NEW YORK, NY,US, vol. 13, no. 3, 1991, pages 447 - 458, XP001010493, ISSN: 0892-3973 *
WOLF B L ET AL: "TREATMENT OF AIDS PATIENTS WITH TRANSFER FACTOR", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 79, no. 1, 1987, pages 244, XP001010503, ISSN: 0091-6749 *

Also Published As

Publication number Publication date
EP0853486A2 (en) 1998-07-22
WO1997011667A2 (en) 1997-04-03
CA2233015A1 (en) 1997-04-03
AU7143196A (en) 1997-04-17
EP0858327A2 (en) 1998-08-19
WO1997011666A2 (en) 1997-04-03
CA2233445A1 (en) 1997-04-03
JPH11514990A (en) 1999-12-21
WO1997011666A3 (en) 1997-06-19
WO1997011667A3 (en) 1997-06-12
AU6999096A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
EP0853486A4 (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
EP0853486A3 (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
EP0831873A4 (en) The treatment of hiv and other viral infections using combinatory therapy
PL319021A1 (en) Body weight modulators, appropriate nucleic acid and proteins and their diagnostic and therapeutic application
AU3066992A (en) Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
EP2270046A3 (en) Methods and compositions for the treatment of hemolysis-associated diseases
IL129352A0 (en) Benzimidazole-2- carbamates for the treatment of viral infections and cancer
HUP9801216A3 (en) Dna molecules, preparation thereof and use thereof in gene therapy
AU2993297A (en) Treatment of sickle cell disease, treatment of immune system diseases and other diseases normally associated with sickle cell anemia
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
AU2990695A (en) Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
ZA956993B (en) Methods of inhibiting demyelinating and desmyelinating diseases.
HUP0000318A3 (en) Tumor vaccine and process for the preparation thereof
HUP9901343A3 (en) P53 protein variants and therapeutical uses thereof
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
DE10083095D2 (en) Gene transfer vectors for the therapy of autoimmune diseases and diseases with immunopathogenesis
GB9509461D0 (en) DNA molecules and constructs and their use in the treatment of mastitis
AU5388299A (en) Antibodies for use in targeted and temporary treatment of humans and animals
GEP20012489B (en) Use of Natural Human α-Interferon
ZA93211B (en) Enzyme castration of animals and tumor treatment.
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
EP0655919A4 (en) Treatment of human viral infections.
AU5778098A (en) Therapeutic substance for use in the treatment of aids and immuno-allergical diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980424

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

A4 Supplementary search report drawn up and despatched

Effective date: 20010813

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

18D Application deemed to be withdrawn

Effective date: 20010403

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1015268

Country of ref document: HK